Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $1.7 million.

  • Sutro Biopharma's Other Non-Current Liabilities changed 0.0% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.7 million for FY2024, which is 0.0% changed from last year.
  • Sutro Biopharma's Other Non-Current Liabilities amounted to $1.7 million in Q3 2025, which was down 0.0% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Other Non-Current Liabilities registered a high of $1.7 million during Q4 2023, and its lowest value of $119000.0 during Q4 2022.
  • In the last 5 years, Sutro Biopharma's Other Non-Current Liabilities had a median value of $1.6 million in 2021 and averaged $1.1 million.
  • As far as peak fluctuations go, Sutro Biopharma's Other Non-Current Liabilities plummeted by 9116.28% in 2022, and later skyrocketed by 132352.94% in 2023.
  • Sutro Biopharma's Other Non-Current Liabilities (Quarter) stood at $146000.0 in 2021, then decreased by 18.49% to $119000.0 in 2022, then surged by 1323.53% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025.
  • Its Other Non-Current Liabilities was $1.7 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.7 million in Q1 2025.